As per an announcement by a clinical-stage biotechnology company on 12 August 2020 the Clinical Trial Application (CTA) has been approved in the Netherlands for initiation of a first-in-human clinical trial of KCP506 (first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist) for chronic neuropathic pain treatment.

The safety and efficacy of KCP506 will be evaluated in healthy individuals in this double-blind, placebo-controlled, single ascending dose and multiple ascending dose study. The phase 1 clinical trials of KCP506 have been scheduled later in 2020. This regulatory approval marks a critical milestone for this organization to evaluate the novel non-opioid in the clinic, mentioned the company’s CEO. KCP506 has been believed to have the probability of a disease-modifying therapy devoid of CNS side effects comprising addiction. The α9α10 nAChR antagonists have confirmed its strong anti-neuroinflammatory, pain-relieving potential and neuroprotective outcomes in many preclinical models. KCP506 have the potential of easing chronic pain progression. Different chronic neuropathic pain comprising of diabetic neuropathy, radiculopathy, chemotherapy-induced peripheral neuropathy may benefit from KCP506.

This biotechnology company collaborated with a subsidiary of Roche in April 2018 dedicated to developing first in class α9α10 nAChR antagonists for chronic pain treatment.